Regarding mitotic inhibitors in acute leukemias, preclinical data suggest a very good response of complex karyotype AML to PLK1 inhibition [21] and of cohesion-mutated AML to disruption of APC/CCDC20 function [150]. The gene discussed is PLK1; the disease is acute leukemia.